{"id":"NCT00688701","sponsor":"Sanofi","briefTitle":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter 12-week Study Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Not Treated With Antidiabetic Agents","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-05","primaryCompletion":"2009-12","completion":"2009-12","firstPosted":"2008-06-03","resultsPosted":"2016-12-12","lastUpdate":"2016-12-12"},"enrollment":361,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Lixisenatide (AVE0010)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DEVICE","name":"Pen auto-injector","otherNames":["OptiClikÂ®"]}],"arms":[{"label":"Placebo (Two-Step Titration)","type":"PLACEBO_COMPARATOR"},{"label":"Placebo (One-Step Titration)","type":"PLACEBO_COMPARATOR"},{"label":"Lixisenatide (Two-Step Titration)","type":"EXPERIMENTAL"},{"label":"Lixisenatide (One-Step Titration)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, used in a 2-step dose titration regimen in monotherapy, over a period of 12 weeks of treatment.\n\nThe primary objective is to assess the effects of lixisenatide, in comparison to placebo, on glycemic control using a 2-step dose titration regimen in terms of glycosylated hemoglobin (HbA1c) reduction (absolute change) at Week 12.\n\nSecondary objectives are to assess the effects of lixisenatide, in comparison to placebo, on glycemic control in terms of HbA1c reduction when it is used in a one-step dose titration regimen over a period of 12 weeks, body weight, fasting plasma glucose (FPG), 2-hour postprandial plasma glucose (PPG) after a standardized meal, to assess the safety and tolerability, pharmacokinetics (PK) and anti-lixisenatide antibody development.","primaryOutcome":{"measure":"Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"Placebo (Combined)","deltaMin":-0.19,"sd":0.121},{"arm":"Lixisenatide (Two-Step Titration)","deltaMin":-0.73,"sd":0.116},{"arm":"Lixisenatide (One-Step Titration)","deltaMin":-0.85,"sd":0.119}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":25},"locations":{"siteCount":12,"countries":["United States","Belgium","India","Israel","Japan","Mexico","Poland","Romania","Russia","South Korea","Tunisia","Ukraine"]},"refs":{"pmids":["22432104","38770818"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":61},"commonTop":["Nausea","Headache","Vomiting","Dizziness"]}}